NZ538686A - Novel imidazopyrazines as cyclin dependent kinase inhibitors - Google Patents

Novel imidazopyrazines as cyclin dependent kinase inhibitors

Info

Publication number
NZ538686A
NZ538686A NZ538686A NZ53868603A NZ538686A NZ 538686 A NZ538686 A NZ 538686A NZ 538686 A NZ538686 A NZ 538686A NZ 53868603 A NZ53868603 A NZ 53868603A NZ 538686 A NZ538686 A NZ 538686A
Authority
NZ
New Zealand
Prior art keywords
compound
nr5r6
alkyl
group
aryl
Prior art date
Application number
NZ538686A
Other languages
English (en)
Inventor
Kamil Paruch
Timothy J Guzi
Michael P Dwyer
Ronald J Doll
Viyyoor M Girijavallabhan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NZ538686A publication Critical patent/NZ538686A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ538686A 2002-09-23 2003-09-19 Novel imidazopyrazines as cyclin dependent kinase inhibitors NZ538686A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41290602P 2002-09-23 2002-09-23
PCT/US2003/029456 WO2004026310A1 (en) 2002-09-23 2003-09-19 Novel imidazopyrazines as cyclin dependent kinase inhibitors

Publications (1)

Publication Number Publication Date
NZ538686A true NZ538686A (en) 2008-01-31

Family

ID=32030939

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ538686A NZ538686A (en) 2002-09-23 2003-09-19 Novel imidazopyrazines as cyclin dependent kinase inhibitors

Country Status (13)

Country Link
US (2) US7186740B2 (cg-RX-API-DMAC7.html)
EP (1) EP1542693A1 (cg-RX-API-DMAC7.html)
JP (1) JP2006503838A (cg-RX-API-DMAC7.html)
KR (1) KR20060010709A (cg-RX-API-DMAC7.html)
CN (1) CN1694706A (cg-RX-API-DMAC7.html)
AR (1) AR041346A1 (cg-RX-API-DMAC7.html)
AU (1) AU2003275031B2 (cg-RX-API-DMAC7.html)
CA (1) CA2499874A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05003119A (cg-RX-API-DMAC7.html)
NZ (1) NZ538686A (cg-RX-API-DMAC7.html)
TW (1) TW200412967A (cg-RX-API-DMAC7.html)
WO (1) WO2004026310A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200502380B (cg-RX-API-DMAC7.html)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
JP2005530739A (ja) 2002-04-19 2005-10-13 セルラー ジェノミクス，インコーポレーテッド イミダゾ［１，２−ａ］ピラジン−８−イルアミン、生成方法、および使用方法
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
KR101173510B1 (ko) 2002-08-23 2012-08-21 슬로안-케테링인스티튜트퍼캔서리서치 에포틸론, 이의 중간물질과 유사체의 합성 및 이들의 용도
AU2003270489A1 (en) 2002-09-09 2004-03-29 Cellular Genomics, Inc. 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
JP4799864B2 (ja) * 2002-09-23 2011-10-26 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのイミダゾピラジン
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
US7160885B2 (en) * 2003-02-10 2007-01-09 Cgi Pharmaceuticals, Inc. Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity
US20060183746A1 (en) * 2003-06-04 2006-08-17 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005014599A1 (en) * 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
WO2005019220A2 (en) * 2003-08-11 2005-03-03 Cellular Genomics Inc. Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity
WO2005085252A1 (en) * 2004-03-04 2005-09-15 Biofocus Discovery Limited Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
EP1858879B1 (en) * 2005-01-14 2012-06-06 Gilead Connecticut, Inc. 1,3-diaryl substituted ureas as modulators of kinase activity
US7777040B2 (en) 2005-05-03 2010-08-17 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
JP2009507032A (ja) 2005-09-02 2009-02-19 アボット・ラボラトリーズ 新規なイミダゾ系複素環
US7700773B2 (en) 2005-09-09 2010-04-20 Schering Corporation 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridines, pyrazolo[1,5-c]pyrimidines and 2H-indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridines, and imidazo[1,5-a]pyrazines as cyclin dependent kinase inhibitors
AR056517A1 (es) * 2005-09-16 2007-10-10 Schering Corp Composiciones y metodos farmaceuticos utilizando temozolomida y un inhibidor de la proteina quinasa
TW200803863A (en) 2005-11-10 2008-01-16 Schering Corp Method for inhibiting protein kinases
US20070117804A1 (en) * 2005-11-10 2007-05-24 Schering Corporation Imidazopyrazines as protein kinase inhibitors
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
JP5693850B2 (ja) 2007-02-06 2015-04-01 リクスト・バイオテクノロジー，インコーポレイテッド オキサビシクロヘプタンおよびオキサビシクロヘプテン、それらの製造および使用
EP2185173A4 (en) * 2007-08-03 2011-01-12 Lixte Biotechnology Inc USE OF PHOSPHATASES FOR THE TREATMENT OF NEUROBLASTOMES AND MEDULLOGASTOMES
CN101854804B (zh) 2007-10-01 2014-07-23 利克斯特生物技术公司 Hdac抑制剂
JP5496915B2 (ja) 2008-02-13 2014-05-21 シージーアイ ファーマシューティカルズ，インコーポレーテッド ６−アリール−イミダゾ［１，２−ａ］ピラジン誘導体、その製造方法、及びその使用方法
WO2010014220A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
CA2730428A1 (en) * 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
ES2590804T3 (es) 2008-12-08 2016-11-23 Gilead Connecticut, Inc. Inhibidores de Imidazopyrazine Syk
SG10201707798SA (en) 2008-12-08 2017-10-30 Gilead Connecticut Inc Imidazopyrazine syk inhibitors
WO2011028638A1 (en) 2009-09-04 2011-03-10 Schering Corporation Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
PH12012500778A1 (en) 2009-10-30 2012-11-26 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
AU2011226689B2 (en) 2010-03-11 2016-09-01 Kronos Bio, Inc. Imidazopyridines Syk inhibitors
US20140135319A1 (en) * 2010-12-17 2014-05-15 Bayer Intellectual Property Gmbh 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
EP2651944B1 (en) * 2010-12-17 2015-09-23 Bayer Intellectual Property GmbH Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
ES2575092T3 (es) 2011-06-27 2016-06-24 Janssen Pharmaceutica, N.V. Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxalina
ES2855575T3 (es) 2012-06-26 2021-09-23 Janssen Pharmaceutica Nv Combinaciones que comprenden compuestos de 4-metil-[1,2,4]triazolo[4,3-a]quinoxalina como inhibidores de PDE2 e inhibidores de PDE10 para su uso en el tratamiento de trastornos neurológicos o metabólicos
ES2607184T3 (es) 2012-07-09 2017-03-29 Janssen Pharmaceutica, N.V. Inhibidores de la enzima fosfodiesterasa 10
JP2016516772A (ja) 2013-04-09 2016-06-09 リクスト・バイオテクノロジー，インコーポレイテッド オキサシクロヘプタン及びオキサビシクロヘプテンの配合物
NZ715776A (en) 2013-07-30 2017-04-28 Gilead Connecticut Inc Polymorph of syk inhibitors
KR20170116203A (ko) 2013-07-30 2017-10-18 질레드 코네티컷 인코포레이티드 Ｓｙｋ 억제제의 제제
DK3076976T3 (da) 2013-12-04 2020-12-07 Kronos Bio Inc Fremgangsmåder til behandling af cancer
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
EA201790086A1 (ru) 2014-07-14 2017-07-31 Джилид Сайэнс, Инк. Комбинации для лечения раковых заболеваний
WO2017087409A1 (en) 2015-11-18 2017-05-26 Genzyme Corporation Biomarker of polycystic kidney disease and uses thereof
BR112019011627A2 (pt) 2016-12-08 2019-11-12 Lixte Biotechnology Inc oxabiciclo-heptanos para modulação da resposta imunológica
WO2019040298A1 (en) 2017-08-25 2019-02-28 Gilead Sciences, Inc. SYK INHIBITORY POLYMORPHS
US11339168B2 (en) 2019-02-22 2022-05-24 Kronos Bio, Inc. Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors
WO2022061155A1 (en) * 2020-09-17 2022-03-24 The Translational Genomics Research Institute Imidazopyridazine and imidazopyrazine compounds as inhibitors of cdk7
CN114042065B (zh) * 2021-11-26 2024-03-15 长沙拜特生物科技研究所有限公司 一种复方甲苯咪唑透皮溶液剂及其制备方法
WO2025199359A1 (en) * 2024-03-21 2025-09-25 The Translational Genomics Research Institute Methods of modulating cdk7 and flt3 using fused bicyclic compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797764A (en) * 1986-01-27 1989-01-10 Minnesota Mining And Manufacturing Company Recording disk with low total indicated runout
FR2607813B1 (fr) 1986-12-05 1989-03-31 Montpellier I Universite Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique
PT778277E (pt) 1995-12-08 2003-11-28 Pfizer Derivados heterociclicos substituidos como antagonistas do crf
EP1301511A2 (en) 2000-07-14 2003-04-16 Bristol-Myers Squibb Pharma Company IMIDAZO 1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
GEP20043367B (en) 2000-07-26 2004-06-10 Bristol Myers Squibb Co N-[5-[[[5-Alkyl-2-Oxazolyl]Methyl]Thio]-2-Thiazolyl Carboxamide Inhibitors of Cyclin Dependent Kinases
CA2436487A1 (en) * 2001-01-30 2002-08-08 Cytopia Pty Ltd. Methods of inhibiting kinases
JP2005530739A (ja) 2002-04-19 2005-10-13 セルラー ジェノミクス，インコーポレーテッド イミダゾ［１，２−ａ］ピラジン−８−イルアミン、生成方法、および使用方法
JP4799864B2 (ja) * 2002-09-23 2011-10-26 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのイミダゾピラジン

Also Published As

Publication number Publication date
AU2003275031A1 (en) 2004-04-08
US7186740B2 (en) 2007-03-06
WO2004026310A8 (en) 2005-06-30
AU2003275031B2 (en) 2006-08-17
US20070155751A1 (en) 2007-07-05
US20040072835A1 (en) 2004-04-15
CA2499874A1 (en) 2004-04-01
TW200412967A (en) 2004-08-01
WO2004026310A1 (en) 2004-04-01
AR041346A1 (es) 2005-05-11
ZA200502380B (en) 2005-09-27
JP2006503838A (ja) 2006-02-02
EP1542693A1 (en) 2005-06-22
KR20060010709A (ko) 2006-02-02
MXPA05003119A (es) 2005-06-22
CN1694706A (zh) 2005-11-09

Similar Documents

Publication Publication Date Title
US7186740B2 (en) Imidazopyrazines as cyclin dependent kinase inhibitors
EP1543008B1 (en) Imidazopyrazines as cyclin dependent kinase inhibitors
CA2499639C (en) Imidazopyridines as cyclin dependent kinase inhibitors
EP1720883B1 (en) Pyrazolotriazines as kinase inhibitors
NZ539164A (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
EP1539750B1 (en) Pyrazolopyridines as cyclin dependent kinase inhibitors
AU2007200401A1 (en) Imidazopyrazines as cyclin dependent kinase inhibitors
HK1072056B (en) Imidazopyrazines as cyclin dependent kinase inhibitors
HK1071758B (en) Pyrazolopyridines as cyclin dependent kinase inhibitors

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed